EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2)

Esther Natalie Oliva iD, Maria Cuzzola, Matteo Della Porta, Anna Candoni iD, Prassede Salutari, Giuseppe A Palumbo iD, Gianluigi Reda, Giuseppe Iannì, Matteo Zampini iD, Saverio D'Amico, Giovanni Tripepi, Debora Capelli und 13 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252111646 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Esther Natalie Oliva und 24 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, 89124 Reggio di Calabria, Italy. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Nucleophosmin, Azacitidine, Remission Induction. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Unconditional funding support for the undertaking of this trial was provided by BMS., BMS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The achievement of complete remission (CR) is crucial for acute myeloid leukemia (AML) patients undertaking curative therapy, but relapse often occurs within months, highlighting the need for strategies to prolong disease-free survival (DFS). Our phase III study compared the efficacy and safety of azacitidine (AZA) to best supportive care (BSC) in elderly AML patients who achieved CR following intensive induction and consolidation therapy. This ancillary study (QOL-ONE Trans-2) evaluated biological changes in bone marrow using Next-Generation Sequencing (NGS). We analyzed baseline, randomization, and 6-month post-remission samples from 24 patients (median age of 71 and 12 males). High-throughput NGS targeted 350 myeloid malignancy-related genes, considering variants with a variant allele frequency ≥ 4%. At diagnosis, all patients had 5 to 17 (median = 10) mutations, with DNMT3A (42%), NPM1 (33%), and TET2 (33%) being most frequent. FANCA mutations in four patients were linked to a higher relapse risk (HR = 4.96, p = 0.02) for DFS at both 2 and 5 years. Further HLA-specific NGS analyses are ongoing to confirm these results and their therapeutic implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteNucleophosminAzacitidineRemission InductionHumansMaleAgedFemaleAged, 80 and overTranslational Research, BiomedicalAntimetabolites, AntineoplasticMutationMiddle AgedHigh-Throughput Nucleotide SequencingDNA Methyltransferase 3ADNA (Cytosine-5-)-MethyltransferasesDisease-Free SurvivalTreatment OutcomeDNA-Binding ProteinsDioxygenases

Stichwörter der Autor:innen

acute myeloid leukemiaazacitidinedisease-free survivalmalignancy-related genes

Substanzen

NucleophosminAzacitidineNPM1 protein, humanAntimetabolites, AntineoplasticDNA Methyltransferase 3ADNMT3A protein, humanDNA (Cytosine-5-)-MethyltransferasesTET2 protein, humanDNA-Binding ProteinsDioxygenases

Autor:innen und Institutionen

  • Hematology Unit, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, 89124 Reggio di Calabria, Italy.
  • UOSD Tipizzazione Tissutale, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, 89124 Reggio di Calabria, Italy.
  • IRCCS Humanitas Research Hospital, 20089 Milan, Italy.
  • Clinica Ematologica, ASUFC, University of Udine, 33100 Udine, Italy.
  • Dipartimento Oncologico-Ematologico Ospedale Civile Spirito Santo Pescara, 65124 Pescara, Italy.
  • Dipartimento di Scienze Mediche Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, 95123 Catania, Italy.

ORCID-Profile: Esther Natalie Oliva, Anna Candoni, Giuseppe A Palumbo, Matteo Zampini, Pasquale Niscola, Pellegrino Musto, Yasuhito Nannya

Förderung

  • Unconditional funding support for the undertaking of this trial was provided by BMS.
  • BMS

Zitieren

APA

Oliva, E. N., Cuzzola, M., Porta, M. D., Candoni, A., Salutari, P., Palumbo, G. A., Reda, G., Iannì, G., Zampini, M., D'Amico, S., Tripepi, G., Capelli, D., Alati, C., Cannatà, M. C., Niscola, P., Serio, B., Barillà, S., Musto, P., Vigna, E., …, & Mammì, C. (2024). Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111646

Vancouver

Oliva EN, Cuzzola M, Porta MD, Candoni A, Salutari P, Palumbo GA, et al. Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2). International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111646

BibTeX
@article{Oliva2024,
  author = {Oliva, Esther Natalie and Cuzzola, Maria and Porta, Matteo Della and Candoni, Anna and Salutari, Prassede and Palumbo, Giuseppe A and Reda, Gianluigi and Iannì, Giuseppe and Zampini, Matteo and D'Amico, Saverio and Tripepi, Giovanni and Capelli, Debora and Alati, Caterina and Cannatà, Maria Concetta and Niscola, Pasquale and Serio, Bianca and Barillà, Santina and Musto, Pellegrino and Vigna, Ernesto and Melillo, Lorella Maria Antonia and Tripepi, Rocco and Zannier, Maria Elena and Nannya, Yasuhito and Ogawa, Seishi and Mammì, Corrado},
  title = {Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2)},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252111646}
}
Kostenlos starten →